PQA 06 - Genitourinary Cancer, Gynecological Cancer, and Health Care Access and Engagement

Presentations

• 02:15pm - 03:30pm ET

  Unknown Causes of Death in Localized Prostate Cancer: Long-Term Data from Two Phase III Trials

  Speaker: Abdenour Nabid, MD - CHUS, Sherbrooke
• 02:15pm - 03:30pm ET

  The Utilization of Dosimetry with Lu-177-PSMA-617 Radiopharmaceutical Treatments: Does Dosimetry Affect Treatment Change?

  Speaker: Caryn Cobb, MD - University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh
• 02:15pm - 03:30pm ET

  Low-Dose-Rate Brachytherapy for Focal Salvage of Prostate Cancer Local Recurrence Using Scintigraphic Guidance

  Speaker: Jay Ciezki, MD - Cleveland Clinic, Cleveland
• 02:15pm - 03:30pm ET

  Updated Results of a Phase I Trial of a Prostatic Urethral Lift Implant with SAbR for Men with Prostate Cancer and Benign Prostatic Hyperplasia

  Speaker: Reena Kudchadker, BS - UT Southwestern Medical Center, Dallas
• 02:15pm - 03:30pm ET

  Rectal Spacing in Large-to-Very-Large Prostates: Balloon vs. Hydrogel Spacer Quality and OAR Dose

  Speaker: Shawn Zimberg, MD - Advanced Radiation Centers of New York, North Hills
• 02:15pm - 03:30pm ET

  Neutron Radiotherapy with Concurrent Checkpoint Inhibitor in Patients with Advanced Urothelial Carcinoma (aUC): Results from a Phase II Clinical Trial

  Speaker: Ting Martin Ma, MD, PhD - University of Washington, Seattle
• 02:15pm - 03:30pm ET

  Evaluation of Organ at Risk Dose Variation under ATP only Workflow Compared with ATS in MRI Guided Prostate SBRT

  Speaker: Swarupa Mitra, MD, MBA, MBBS - Rajiv Gandhi Cancer Institute & Research Centre, Delhi
• 02:15pm - 03:30pm ET

  Trimodality Bladder Preservation Therapy Outcomes in Patients with Histologic Subtypes of Urothelial Carcinoma

  Speaker: Ting Martin Ma, MD, PhD - University of Washington, Seattle
• 02:15pm - 03:30pm ET

  TP53 Mutation Status and Pathologic Lymph Node Involvement in Prostate Cancer: Implications for Elective Nodal Irradiation

  Speaker: Victor Lee, MD, BS - Yale New Haven Hospital, Middletown
• 02:15pm - 03:30pm ET

  Long-Term Outcomes and Toxicity Following Salvage Whole Gland or Focal HDR Brachytherapy for Recurrent Prostate Cancer: A Single-Institution Experience

  Speaker: Dina Elhabashy, MD, MS - Corewell Health William Beaumont University Hospital, Royal Oak
• 02:15pm - 03:30pm ET

  A Phase I/II Dose-Escalation Study Evaluating the Safety of 21 Gy, 23 Gy, and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy: An Interim Report

  Speaker: Michael Padgett, MD - Washington University in St. Louis, St. Louis
• 02:15pm - 03:30pm ET

  Clinical Validation of a Privacy-Preserving LLM for End-to-End CTCAE Toxicity Assessment in Prostate Cancer Radiotherapy

  Speaker: Ahmed Ghanem, MD, PhD - Henry Ford Cancer Institute/Alexandria University, Detroit
• 02:15pm - 03:30pm ET

  Discordance between MRI-Targeted and Systematic Core Biopsy in Identifying the Highest-Grade Focus: Implications for Intraprostatic Boost

  Speaker: Chaewon Hwang, MD - Tufts Medical Center | Beth Israel Deaconess Medical Center, Boston
• 02:15pm - 03:30pm ET

  Safety of Spine Radiotherapy Delivered within 6 Months of Lu-177 PSMA Radioligand Therapy in Metastatic Prostate Cancer

  Speaker: Joshua Qian, MD - Memorial Sloan Kettering Cancer Center, New York
• 02:15pm - 03:30pm ET

  Intensity Modulated Proton Therapy (IMPT) for Localized Prostate Cancer: Disease Control Outcomes in Intermediate to Very-High Risk Patients

  Speaker: Marcio Fagundes, MD - Miami Cancer Institute, Miami
• 02:15pm - 03:30pm ET

  Gastrointestinal and Renal Adverse Events following Kidney SBRT for Renal Cell Carcinoma: Impact of Recent Systemic Therapy Use

  Speaker: Keaton Rummel, MD - Mayo Clinic College of Medicine and Science Rochester, Rochester
• 02:15pm - 03:30pm ET

  Clinicopathologic Predictors of PSMA-PET Detection, Recurrence Pattern, and Biochemical Outcome Following Salvage Radiotherapy after Radical Prostatectomy

  Speaker: Ramotallah Jubril, MS - Purdue University, West Lafayette
• 02:15pm - 03:30pm ET

  High-Throughput Dosimetric Profiling of Pelvic Organs at Risk and Lymphopenia in Prostate Radiotherapy

  Speaker: Lukasz Kuncman, MD, DSc, PhD - Medical University of Lodz, Lodz
• 02:15pm - 03:30pm ET

  Blood Urea Nitrogen as a Prognostic Biomarker In Bladder Cancer

  Speaker: Prakash Chaudhary, PhD - Cedars-Sinai Medical Center, Los Angeles
• 02:15pm - 03:30pm ET

  Wearable Artificial Intelligence Powered Device for Optimal Pelvic Radiation Therapy

  Speaker: Fan Zhu, MD, BS - UMass Memorial Medical Center, Worcester
• 02:15pm - 03:30pm ET

  Evaluating Pretreatment PSMA PET/CT Radiomics in Prostate Cancer

  Speaker: Lakshmi Rekha Narra, MD - Rutgers Cancer Institute of New Jersey, New Brunswick
• 02:15pm - 03:30pm ET

  Preoperative Biopsy Genomic Classifier and Secondary Radiotherapy after Radical Prostatectomy: National Real-World Evidence

  Speaker: Thomas Kole, MD, PhD - Memorial Sloan Kettering Monmouth, Middletown
• 02:15pm - 03:30pm ET

  Outcomes after Pelvic Radiotherapy and Androgen Deprivation Therapy for Pathologic Node-Positive Prostate Cancer in the PSMA PET Era

  Speaker: Sofia Romano, BS - Keck School of Medicine of USC, Los Angeles
• 02:15pm - 03:30pm ET

  Determining the Effect of Prostate Size on the Quality-of-Life Outcomes for Prostate Cancer Patients Undergoing Definitive Radiotherapy

  Speaker: Allen Khodab, MD - University of Miami - Sylvester Cancer Center, Miami
• 02:15pm - 03:30pm ET

  Polygenic Scores as a Genetically Informed Approach to Prostate Cancer Risk Stratification

  Speaker: Daniel Sabater Minarim, MS - UCSD Health, La Jolla
• 02:15pm - 03:30pm ET

  Prediction Model Construction and Clinical Utility of Positive Surgical Margins in Apical Prostate Tumors Using Multimodal MRI

  Speaker: Yize Zhao, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  Comorbidity and Bladder Dose-Volume Interplay in Grade-Specific Late Hemorrhagic Radiation Cystitis Following Post-Prostatectomy Radiotherapy: An Asian Cohort

  Speaker: Hsing-Ju Li, MS, RN - National Taiwan University Hospital, Taipei
• 02:15pm - 03:30pm ET

  Neoadjuvant Chemotherapy vs. Antibody Drug Conjugate/Immune Checkpoint Inhibitor Prior to Tri-Modality Treatment for Selected Patients with Muscle-Invasive Bladder Cancer

  Speaker: Shang-Bin Qin, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  The Dosimetric Advantages of Intensity-Modulated Proton Therapy (IMPT) in the Full Coverage Radiation of Primary and All Metastatic Lesions in Patients with Oligometastatic Prostate Cancer

  Speaker: Lin Ma, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  Survival Outcomes and Toxicity with Reduced-Dose ARPI Therapy: Rationale for the ENHANCE Phase III Trial

  Speaker: Ananya Choudhury, PhD, MA MRCP FRCR - The Christie NHS Foundation Trust and University of Manchester, Manchester
• 02:15pm - 03:30pm ET

  PRO-BOOST-N: Phase II/III Trial of Prostate-First vs. Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer

  Speaker: Mateusz Bilski, MD, PhD - Lublin Region Oncology Center, Lublin
• 02:15pm - 03:30pm ET

  Impact of Posterior PTV Margin on the Treatment Efficiency and Adverse Effects of Radical Radiotherapy for Prostate Cancer Patients

  Speaker: Lin Ma, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  Combination Low-Dose-Rate Brachytherapy and Stereotactic Body Radiation Therapy (SBRT) In Localized Intermediate- and High-Risk Prostate Cancer: A Single Institution Experience

  Speaker: Benjamin Tran, MD - Mount Sinai Hospital, New York
• 02:15pm - 03:30pm ET

  Development of Salvage Brachytherapy-Specific Genitourinary Toxicity Nomograms after Prostate Reirradiation

  Speaker: Mateusz Bilski, MD, PhD - Lublin Region Oncology Center, Lublin
• 02:15pm - 03:30pm ET

  Interfraction Positional Stability of a Biodegradable Balloon Rectal Spacer during Prostate SBRT

  Speaker: Tomer Charas, MD - Rambam Medical Center, Haifa
• 02:15pm - 03:30pm ET

  The Safety and Efficacy of PSMA-PET-Guided Comprehensive Radiotherapy for Oligo-Residual Disease after Treatment in High-Volume Metastatic Prostate Cancer

  Speaker: Qing-hua Peng, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  Post-Treatment PSMA PET as a Predictor of PSA Relapse in Primary Prostate Cancer

  Speaker: Tianyu Justin Yang, PhD - Rutgers Cancer Institute of New Jersey, New Brunswick
• 02:15pm - 03:30pm ET

  Metastasis Directed Radiation Therapy for Oligometastatic and Oligoprogressive Renal Medullary Carcinoma

  Speaker: Shlok Mohanty, MD - JPS Health, Fort Worth
• 02:15pm - 03:30pm ET

  Baseline Urinary Symptom Burden, but not DIL/CTV Ratio, Correlates with Late GU Toxicity After Single-Dose Prostate Radiotherapy with Simultaneous Integrated Dominant Intraprostatic Lesion Boost

  Speaker: Carlo Greco, MD - CCU, Lisbon
• 02:15pm - 03:30pm ET

  Impact of Locoregional Chemohyperthermia in Recurrent Non-Muscle-Invasive Bladder Cancer: Cohort Follow-Up Study

  Speaker: C. Paola Tello Valverde, PhD, MS - Amsterdam University Medical Center (AUMC), Amsterdam
• 02:15pm - 03:30pm ET

  Stereotactic Body Radiotherapy in Medically Inoperable Urinary Tract Urothelial Carcinoma: A Retrospective Experience

  Speaker: Hiroshi Onishi, MD, PhD - University of Yamanashi, Chuo-shi 409-3898
• 02:15pm - 03:30pm ET

  Adaptive Kidney Irradiation: The Impact of CT-Based Adaptive Radiotherapy on Kidney Cancer SBRT Delivery

  Speaker: Elizabeth Ademuwagun, MD - Temple University Hospital/Fox Chase Cancer Center, Philadelphia
• 02:15pm - 03:30pm ET

  Sacral Plexus Dose Constraints in the SBRT Era: A Retrospective Analysis of Radiation-Induced Lumbosacral Plexopathy

  Speaker: Nan Zhao, MD, PhD - Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland
• 02:15pm - 03:30pm ET

  Impact of Prediagnostic Primary Care Utilization on Bladder Cancer Metastasis and Mortality

  Speaker: Nikitha Kalahasti, BS - University of California at San Diego, La Jolla
• 02:15pm - 03:30pm ET

  Patterns of Care and Survival in Cribriform Prostate Carcinoma in SEER

  Speaker: Jonathon Cummock, MD, PhD - University of Wisconsin Hospitals and Clinics, Madison
• 02:15pm - 03:30pm ET

  Toxicity and Efficacy of Radiotherapy with or without Pelvic Prophylactic Radiotherapy in Patients with Oligometastatic Prostate Cancer

  Speaker: Xin Qi, MD, MS - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  What Is the Procedure-Related Complication Rate Associated with Iodinated Hydrogel Spacer Use in Prostate Radiotherapy? A Large Single-Center Experience

  Speaker: Paul Kelly, MB - Cork University Hospital, Cork
• 02:15pm - 03:30pm ET

  Evaluation of the Efficacy and Safety of Particle Therapy for Kidney Cancer through a Multicenter Registry Study and Meta-Analysis

  Speaker: Kentaro Nishioka, MD, PhD - Hokkaido University, Sapporo
• 02:15pm - 03:30pm ET

  APP4-Guided Selection of Active Surveillance vs. SBRT for Favorable-Risk Prostate Cancer: Pooled Prospective Registry and Trial Outcomes

  Speaker: Ruben Del Castillo, MD - Sunnybrook Odette Cancer Centre, Toronto
• 02:15pm - 03:30pm ET

  Targeting Metabolic Dependencies with Precision Nutrition and Radiotherapy in MYC- and PTEN/AKT-Driven Prostate Cancer

  Speaker: Shan Xu, MD - Abbotts Square, Philadelphia
• 02:15pm - 03:30pm ET

  Retrospective Comparison of PULSAR vs. SAbR in Combination with Immunotherapy for Renal Cell Carcinoma

  Speaker: Casey Moore, MD, PhD, BS - University of Texas Southwestern Medical Center, Dallas
• 02:15pm - 03:30pm ET

  Dosimetric Benefit of Online Adaptive Radiotherapy In Bladder Cancer

  Speaker: Goda Kalinauskaite, MD - Charite - Universitatsmedizin Berlin, Berlin
• 02:15pm - 03:30pm ET

  Evaluating Prostate Bed Dose Escalation in the Setting of Salvage Radiotherapy and ADT

  Speaker: Alexander Sasse, MD - UCSF Comprehensive Cancer Center, San Francisco
• 02:15pm - 03:30pm ET

  The Guiding Value of PSMA PET/CT Combined with Contrast-Enhanced Prostate MRI for Salvage Radiotherapy in Prostate Cancer Patients with Low PSA Levels: A Single-Center Exploratory Study

  Speaker: Le Mao, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  Effectiveness and Safety of Relugolix in Patients With Advanced Prostate Cancer Receiving Radiation Therapy: 6-Month Subgroup Analysis of the OPTYX Study

  Speaker: Daniel Spratt, MD - University Hospitals Seidman Cancer Center, Case Western Reserve University, Beachwood
• 02:15pm - 03:30pm ET

  SBRT for Oligoprogressive Metastatic Renal Cell Carcinoma: Results of a Single Institution Retrospective Analysis

  Speaker: Ahmed Nawwar, MD, MPH - University of Kansas Cancer Center, Kansas City
• 02:15pm - 03:30pm ET

  Dosimetric Feasibility of Genomically Stratified Dominant Lesion Boost In Two-Fraction Prostate SBRT

  Speaker: Nima Aghdam, MD, MS - NYU Langone Health, New York
• 02:15pm - 03:30pm ET

  Association of Pre-Treatment Sacral Bone Marrow Morphology with Radiation-Induced Lymphopenia in Prostate Cancer

  Speaker: Konrad Stawiski, MD, PhD - Medical University of Lodz, Lodz
• 02:15pm - 03:30pm ET

  Dosimetric Outcomes of Cytoreductive Stereotactic Body Radiotherapy (SBRT) for Metastatic Renal Cell Carcinoma (mRCC): Data from the CYTOSHRINK Trial

  Speaker: Laura Collie, MD - Juravinski Cancer Center, Hamilton
• 02:15pm - 03:30pm ET

  Impact of Short-Term ADT on Survival in Unfavorable Intermediate-Risk Prostate Cancer Treated with Proton-Beam Radiotherapy - A Retrospective Cohort Study

  Speaker: Kayeong Shin, MD - MD Anderson Cancer Center, Houston
• 02:15pm - 03:30pm ET

  Erectile Dysfunction Severity as a Vascular Biomarker Predicting Cardiovascular Mortality in Patients with Prostate Cancer

  Speaker: Mutlay Sayan, MD - Brigham and Women's Hospital/Dana-Farber, Boston
• 02:15pm - 03:30pm ET

  Early Patient-Reported Outcomes following Two-Fraction Prostate SBRT with and without Dominant Lesion Boost

  Speaker: Vianca Santos, DrPH, MPH - NYU Langone Health - Long Island, Mineola
• 02:15pm - 03:30pm ET

  A Comprehensive Population Study of Prostate MR-Linac SBRT: Quantifying Motion-Induced Duty Cycle Variations and Simulated Non-Gated Dosimetry

  Speaker: Kamal Singhrao, PhD - Brigham and Women's Hospital/Dana Farber Cancer Institute, Boston
• 02:15pm - 03:30pm ET

  Comparative Incidence of Severe Lymphopenia in Patients Treated With IMRT Versus IMPT

  Speaker: Kayeong Shin, MD - MD Anderson Cancer Center, Houston
• 02:15pm - 03:30pm ET

  Erectile Dysfunction Severity as a Clinical Marker of High-Grade Prostate Cancer at Presentation

  Speaker: Mutlay Sayan, MD - Brigham and Women's Hospital/Dana-Farber, Boston
• 02:15pm - 03:30pm ET

  Differences In Rectal Dosimetry between Implantable Rectal Spacer Options for Prostate Cancer Radiotherapy

  Speaker: Sean McCauley, MD - Mayo Clinic Arizona, Phonix
• 02:15pm - 03:30pm ET

  Analysis of SBRT for Oligoprogressive Renal Cell Carcinoma Lung Metastases: Impact on Distant Control, Systemic Therapy, and Survival Outcomes

  Speaker: Grace Song, BA - Cleveland Clinic Foundation, Cleveland
• 02:15pm - 03:30pm ET

  Renal Function Preservation after Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Multicenter Real-World Experience

  Speaker: Wojciech Majewski, MD, PhD - Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice
• 02:15pm - 03:30pm ET

  Effect of Prostate-Specific Membrane Antigen PET/CT Guidance on Metastasis-directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer

  Speaker: John Chojnowski, MD, PhD - Hospital of the University of Pennsylvania, Philadelphia
• 02:15pm - 03:30pm ET

  Systematic Review of SBRT after Radical Prostatectomy in Prostate Cancer: Current Evidence and Clinical Outcomes in Both Adjuvant and Salvage Scenarios

  Speaker: Laith Samhouri, MD, MHBA - Jordan University of Science and Technology, Irbid
• 02:15pm - 03:30pm ET

  Dosimetric Impact of Intentional Proximal Seminal Vesicle Targeting In Low-Dose-Rate I-125 Prostate Brachytherapy Monotherapy

  Speaker: Piero Bettoli, MD, MS - Clínica Dávila, Santiago
• 02:15pm - 03:30pm ET

  Effects of Prostate Auto-Planner on Plan Quality, Dosimetric Constraints, and Clinic Workflow: A Real World Comparison

  Speaker: Matthew Trotta, MD - University of Alabama at Birmingham, Birmingham
• 02:15pm - 03:30pm ET

  Spatial Immune Phenotyping Using Histo-Immuno-Radiomics in Patients with Biochemical Recurrence Following Radical Prostatectomy

  Speaker: Oluwaseyi Oderinde, PhD - Purdue University, West Lafayette
• 02:15pm - 03:30pm ET

  Longitudinal Characterization of Rectal Spacing Achieved by Two Commercial Rectal Spacer Products

  Speaker: Ryan Davis, MD - City of Hope National Medical Center, Duarte
• 02:15pm - 03:30pm ET

  Toxicity Outcomes and Patterns of Failure after Whole vs. Partial Gland HDR Brachytherapy as Salvage Treatment for Recurrent Prostate Cancer

  Speaker: Paul Armstrong, MD - University of Maryland Department of Radiation Oncology, Baltimore
• 02:15pm - 03:30pm ET

  Sexual Function after Radiation Therapy: Long-Term Outcomes and Real-World Effectiveness of Sexual Medicines and Devices

  Speaker: Sophia Kim-Wang, MD, PhD - University of Chicago, Chicago
• 02:15pm - 03:30pm ET

  Tumor Control and Normal Tissue Complication Probability Modeling for High Dose Rate Brachytherapy Followed by 5-Fraction SBRT Treatment of Unfavorable Intermediate or High-risk Prostate Cancer Patients with Biodegradable Hydrogel Rectal Spacer Placement

  Speaker: Ke (Colin) Huang, PhD, MS - Indiana University School of Medicine, Indianapolis
• 02:15pm - 03:30pm ET

  Adaptive Planning in a Prospective Bladder Cancer Trial: Dosimetric Outcomes

  Speaker: Katherine Amarell, MD, BS - Cleveland Clinic Foundation, Cleveland
• 02:15pm - 03:30pm ET

  Hydrogel Spacers Hold the Line: Rectal Wall Infiltration is Rare in Prostate SBRT

  Speaker: Mihir Karande, MD - Fox Chase Cancer Center, Philadelphia
• 02:15pm - 03:30pm ET

  Long-Term Efficacy and Safety Outcomes of Dose-Escalated SBRT for Prostate Cancer

  Speaker: John Starner, DO - Northwell Health, Lake Success
• 02:15pm - 03:30pm ET

  Surface-Guided End-Exhale Breath-Hold for Primary Kidney Cancer Stereotactic Ablative Radiotherapy

  Speaker: Siqiu Wang, PhD - University of Texas Southwestern Medical Center, Dallas
• 02:15pm - 03:30pm ET

  Comparative Analysis of Perirectal Spacer Quality for Two FDA-Approved Products

  Speaker: Edmond Yaghoubian, MD - UPMC, Pittsburgh
• 02:15pm - 03:30pm ET

  Cross-Continental Transcriptomic Evaluation of a Multimodal AI-Based Biomarker in Localized Prostate Cancer

  Speaker: Samantha Webking, MD - Moffitt Cancer Center, Tampa
• 02:15pm - 03:30pm ET

  Clinical Outcomes of Rectal Wall Infiltration Following Hydrogel Spacer Placement: A Single-Institution Retrospective Study

  Speaker: Zakaria El Kouzi, MD - MD Anderson Cancer Center, Houston
• 02:15pm - 03:30pm ET

  Stereotactic Body Proton Therapy for Primary Kidney Tumors: Early Outcomes from a Community Cancer Center

  Speaker: Chiachien Wang, MD, PhD - Willis-Knighton Cancer Center, Shreveport
• 02:15pm - 03:30pm ET

  Morphological-Dosimetric Model for Adaptive Radiotherapy Triggering in Bladder Cancer Radiotherapy

  Speaker: Sijuan Huang, - Sun Yat-sen University Cancer Center, Guangzhou
• 02:15pm - 03:30pm ET

  Radiotherapy Fractionation and Travel Burden in Prostate Cancer: A National Analysis of Access, Time Savings and Environmental Impact

  Speaker: Mohyeddine El Sayed, MD - Medical University of South Carolina, Charleston
• 02:15pm - 03:30pm ET

  PSMA PET Response Dynamics after 177Lu-PSMA Radiopharmaceutical Therapy and External Beam Radiotherapy

  Speaker: Arnav Rao, BA - Stanford University School of Medicine, Stanford
• 02:15pm - 03:30pm ET

  Oncologic Outcomes and Toxicity of PULSAR-Based Stereotactic Ablative Radiotherapy (SAbR) with Immunotherapy in Metastatic Urothelial Carcinoma

  Speaker: Yash Soni, MD, BS - UT Southwestern Medical Center, Dallas
• 02:15pm - 03:30pm ET

  Characterizing the Consult to CT-Simulation Interval in the Setting of Screening Colonoscopy Prior to Prostate Radiotherapy in a VA Patient Population

  Speaker: Joan Lee, MD - University Hospitals Cleveland Medical Center, Cleveland
• 02:15pm - 03:30pm ET

  Real World Experience of Stereotactic Body Radiotherapy for Carcinoma Prostate in a Tertiary Care Cancer Center in North India

  Speaker: Lincoln Pujari, MD, MBBS, DNB - Mahamana Pandit Madan Mohan Malaviya Cancer Centre, VARANASI
• 02:15pm - 03:30pm ET

  Effect of Pelvic Radiation on Systemic Gene Expression Changes in a Prospective Study of Non-Metastatic Prostate Cancer

  Speaker: Benjamin George, BA - Medical College of Wisconsin, Milwaukee
• 02:15pm - 03:30pm ET

  The Association between Disease Control and Novel Pathologic or Radiographic Risk Factors in Intermediate-Risk Prostate Cancer (IR-PCa)

  Speaker: Beck French, BA - The Ohio State University College of Medicine, Columbus
• 02:15pm - 03:30pm ET

  Decipher Immune Microenvironment Signatures Predict Radiation Toxicity In Prostate Cancer: A Single-Institution Analysis

  Speaker: John Starner, DO - Northwell Health, Lake Success
• 02:15pm - 03:30pm ET

  Identification of Key Clinical and Dosimetric Predictors for Acute Treatment-Induced Toxicity following Postoperative Prostate Cancer Radiotherapy

  Speaker: Qian Man, MD - Peking University Third Hospital, Beijing
• 02:15pm - 03:30pm ET

  Social Determinants of Health and Psychological Distress in Prostate Cancer Patients Undergoing Radiation Therapy: A Prospective Cohort Study

  Speaker: Teresia Perkins, BS - Boston University School of Medicine (BUSM), Boston
• 02:15pm - 03:30pm ET

  A Tiered Plan-Library-First Workflow Reduces Triggered Online Adaptive Radiotherapy in Postprostatectomy Radiotherapy

  Speaker: Xuemin Li, MD - Peking University Third Hospital, Beijing
• 02:15pm - 03:30pm ET

  Prospective Geometric Assessment for PTV Margin Adaptation in Fiducial-Guided Prostate SBRT

  Speaker: Zuzana Cermakova, MD, PhD - University Hospital Ostrava, Ostrava
• 02:15pm - 03:30pm ET

  Anatomy-Guided Maximized-Volume Spatially Fractionated Radiotherapy Versus Conventional SABR in Oligometastatic Renal Cell Carcinoma: A Retrospective Review of a Prospective Cohort Study

  Speaker: Shanshi Li, PhD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  A Prospective Study on Tumor Detection and PET-guided Radiotherapy Treatment Planning with PSMA-targeted Flotufolastat F-18 Imaging on a Biology-guided Radiotherapy Machine

  Speaker: Chunhui Han, PhD - City of Hope National Medical Center, Duarte
• 02:15pm - 03:30pm ET

  Efficacy and Safety of Salvage Re-Irradiation in Oligoprogressive Prostate Cancer

  Speaker: Huan Zhang, MD, MS - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  Assessing the Prevalence of Pathogenic Germline Variants in Prostate Cancer Patients Managed with Radiation Therapy

  Speaker: Adetolani Odogiyon, BS - Massachusetts General Hospital, Winchester
• 02:15pm - 03:30pm ET

  Long-Term Outcomes after Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Single Institution Experience

  Speaker: Panos Papanikolaou, MD - Johns Hopkins Hospital, Baltimore
• 02:15pm - 03:30pm ET

  External Validation of a Germline Genetic Risk Score for Genitourinary Adverse Events after Prostate Radiotherapy

  Speaker: George Xu, PhD - University of California San Diego, San Diego
• 02:15pm - 03:30pm ET

  Intravesical Prostatic Protrusion: Exploring a Novel Imaging Biomarker for Late Genitourinary Outcomes following Prostate SBRT

  Speaker: Makoto Ito, MD, PhD - Aichi Medical University Hospital, Nagakute
• 02:15pm - 03:30pm ET

  Outcomes of Carbon-Ion Radiotherapy for Very High-Risk Prostate Cancer in a Contemporary Consecutive Cohort

  Speaker: Hiraku Sato, MD, PhD - Yamagata University, Yamagata
• 02:15pm - 03:30pm ET

  Diagnostic Performance of mpMRI and PSMA PET In Local Intraprostatic Radiorecurrent Prostate Cancer: A Radiologic-Pathologic Correlation Study

  Speaker: Esther Yu, MD - UCLA David Geffen School of Medicine/UCLA Medical Center, Los Angeles
• 02:15pm - 03:30pm ET

  PRO-BOOST-LC: Phase II/III Trial of Whole-Gland Boost Strategies vs. SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer

  Speaker: Mateusz Bilski, MD, PhD - Lublin Region Oncology Center, Lublin
• 02:15pm - 03:30pm ET

  Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment (VORTEX) - A Prospective Phase III RCT of Neurovascular-Sparing SBRT

  Speaker: Jonathan Massachi, MD, MS - University of California, Los Angeles, Los Angeles
• 02:15pm - 03:30pm ET

  A Phase II Trial In Progress: Alpha-emitting radioNucliDe or Beta-Emitting RadiOnuclide Combined With MEtastasis-Directed Stereotactic Body Radiotherapy for Oligorecurrent Prostate Adenocarcinoma (ANDROMEDA)

  Speaker: Kekoa Taparra, MD, PhD, MPH - UCLA Health, Los Angeles
• 02:15pm - 03:30pm ET

  The Performance of PET, Multiparametric MRI and Transperineal Prostate Biopsy in Identification of Intraprostatic Tumor Deposits after Prostate Radiation Therapy

  Speaker: R. Hsi, MD - Fred Hutch Cancer Center Peninsula, Poulsbo
• 02:15pm - 03:30pm ET

  Clinical Predictors of Long-Term Urinary Morbidity Following Combination Radiation Therapy for Prostate Cancer

  Speaker: Ryan Lee, - Urology of Greater Atlanta, Stockbridge
• 02:15pm - 03:30pm ET

  Detection and Localization of Unfavorable-Histology Prostate Cancer Using MRI and Whole-Mount Histopathology

  Speaker: Mariluz Rojo Domingo, MS - University of California San Diego, La Jolla
• 02:15pm - 03:30pm ET

  Skeletal-Related Events after Radiotherapy for Non-Spine Bone Metastases in Renal Cell Carcinoma

  Speaker: Harshath Gupta, MD - MD Anderson Cancer Center, Houston
• 02:15pm - 03:30pm ET

  Long-Term Changes in Sexual Function After Carbon Ion Radiotherapy for Localized Prostate Cancer: A Five-Year Prospective Study

  Speaker: Yoshiyuki Miyazawa, MD, PhD - Gunma University Department of Urology, Maebashi
• 02:15pm - 03:30pm ET

  Impact of Age on PSA Kinetics and Oncological Outcomes After Low-Dose-Rate Brachytherapy

  Speaker: Yasushi Nakai, MD, PhD - Nara Medical University, Kashihara
• 02:15pm - 03:30pm ET

  Mechanistic Insights into Radiopharmaceutical Therapy Resistance through Bayesian Analysis of Circulating Tumor Cell Transcriptomes

  Speaker: Keisuke Otani, MD, PhD - Massachusetts General Hospital, Charlestown
• 02:15pm - 03:30pm ET

  Lifetime Risk of Androgen Deprivation Therapy after Active Surveillance for Prostate Cancer

  Speaker: James Janopaul-Naylor, MD - Memorial Sloan Kettering Cancer Center, New York
• 02:15pm - 03:30pm ET

  Clinical vs. MRI Risk Signals In Intermediate-Risk Prostate Cancer Treated with Radiotherapy: Associations with PSA Density and Radiographic ECE/SVI

  Speaker: James Janopaul-Naylor, MD - Memorial Sloan Kettering Cancer Center, New York
• 02:15pm - 03:30pm ET

  Interfractional Dosimetric Variations During MR-guided Radiotherapy as Predictors of Genitourinary Toxicity in Prostate Cancer

  Speaker: Jessica Hossa, MD, MS, BS - Allegheny General Hospital, Pittsburgh
• 02:15pm - 03:30pm ET

  Real-World Outcomes of Daily CBCT-Based Online Adaptive Radical-Intent Bladder Radiotherapy

  Speaker: Olabisi Ogunbiyi, MBBS, BSc - Royal Surrey County Hospital NHS Foundation Trust, London
• 02:15pm - 03:30pm ET

  Is This the Right Fossa? Verification of Prostate Fossa Contouring Volumes Using 18F-Fluciclovine PET/CT

  Speaker: Adam Eakin, MD - Oregon Health and Science University, Portland
• 02:15pm - 03:30pm ET

  Circulating Tumor DNA Dynamics in Oligometastatic Urothelial Carcinoma Treated with Stereotactic Body Radiation Therapy

  Speaker: Dekuang Zhao, DO, PhD - Moffitt Cancer Center, Tampa
• 02:15pm - 03:30pm ET

  Phase 1 Trial of 177 Lu -rhPSMA-10.1 Following PSMA-PET-Guided Post-Prostatectomy Salvage Radiotherapy: Early Response Assessment

  Speaker: Ashesh Jani, MD, MS, FASTRO - Emory University, Atlanta
• 02:15pm - 03:30pm ET

  Prostate Hypofractionation over 20 Years: Long-Term Results from a Single Institution

  Speaker: Katherine Amarell, MD, BS - Cleveland Clinic Foundation, Cleveland
• 02:15pm - 03:30pm ET

  Digital Pathology in Relation to Immune Activation Following Aglatimagene Besadenovec Immunotherapy in Localized Prostate Cancer

  Speaker: Francesca Barone, MD, PhD - Candel Therapeutics, Inc., Needham
• 02:15pm - 03:30pm ET

  Real-World Comparison of Initial Local Treatment Strategies for Gleason Grade 5 Prostate Cancer: Radiotherapy vs. Surgery Cohort Study

  Speaker: Le Mao, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  A Radiomics Based Approach for Predicting Prostate Cancer in PIRADS 3 Lesions on Multi-Parametric MRI

  Speaker: Rikhil Makwana, BA - Chicago Medical School at Rosalind Franklin University, North Chicago
• 02:15pm - 03:30pm ET

  A Confirmative Study of Quantitative Imaging Biomarkers for PSMA-RLT Response and Toxicity

  Speaker: Vincent Li, BS - UW Health Radiation Oncology, Madison
• 02:15pm - 03:30pm ET

  SBRT for Intermediate and High-Risk Prostate Cancer without Fiducials: A Phase II Clinical Trial

  Speaker: Firas Almomen, MBBS - King Saud University Medical City, Riyadh
• 02:15pm - 03:30pm ET

  Prognostic Value of Lesions with Low PSMA Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing PSMA-RLT

  Speaker: Jonathan Benson, BS - University of Wisconsin - Madison, Madison
• 02:15pm - 03:30pm ET

  National Utilization and Cost Patterns of Trimodality Therapy vs. Radical Cystectomy for Muscle-Invasive Bladder Cancer in the United States

  Speaker: Rod Carlo Columbres, DO, BS - Winship Cancer Institute of Emory University, Atlanta
• 02:15pm - 03:30pm ET

  Assessment of CT Simulation-Based Prostate Radiotherapy Plan Robustness Using Serial Cone-Beam CT

  Speaker: Sonia Targ, MD, MS - Kaiser Permanente Los Angeles Medical Center, Los Angeles
• 02:15pm - 03:30pm ET

  Phase I Dose-Escalation of Hypofractionated Pelvic Nodal Proton Radiotherapy with Simultaneous Integrated Prostate Boost

  Speaker: Yomna Khamis, MD - University of Maryland, Baltimore
• 02:15pm - 03:30pm ET

  Safety and Feasibility of Nimotuzumab Combined with Gemcitabine and SABR-Boosted Concurrent Radiotherapy for Muscle Invasive Bladder Cancer: Initial Results from a Phase I/II Trial

  Speaker: Shangbin Qin, MD - Peking University First Hospital, beijing
• 02:15pm - 03:30pm ET

  Determinants of Kidney and Tumor Dose In Single-Timepoint 177 Lu-PSMA-617 Dosimetry

  Speaker: Srikrishna Tirumalareddy, BS - Thomas Jefferson University, Philadelphia
• 02:15pm - 03:30pm ET

  Secondary Lung Tumor in Localized Prostate Cancer Treated with Radiotherapy ± Androgen Depletion Therapy: Long-Term Data from Two Phase III Trials

  Speaker: Abdenour Nabid, MD - CHUS, Sherbrooke
• 02:15pm - 03:30pm ET

  Genitourinary Dosimetry and Early Urinary Quality of Life in a Randomized Prostate SAbR Trial with Planned Dose Heterogeneity

  Speaker: Kishan Pithadia, MD - UT Southwestern Medical Center, Dallas
• 02:15pm - 03:30pm ET

  Improved Correction of Anatomical Distortion in Diffusion-Weighted Prostate MRI

  Speaker: Joshua Kim, BS - Loma Linda University School of Medicine, Vancouver
• 02:15pm - 03:30pm ET

  Radiotherapy for Localized and Metastatic Neuroendocrine Prostate Cancer

  Speaker: Carson Jones, BS - East Carolina University Brody School of Medicine, Greenville
• 02:15pm - 03:30pm ET

  Radiomic Analysis of Pre-Treatment PSMA PET/CT for Prognostic Stratification in Patients with Oligometastatic Castration-Sensitive Prostate Cancer

  Speaker: Yufeng Cao, PhD - University of Maryland Central Maryland Radiation Oncology, Columbia
• 02:15pm - 03:30pm ET

  What Matters Most to Patients with Localized Prostate Cancer: Prospective Preference Data from a Statewide Consortium

  Speaker: Joseph Tang, MD - University of Michigan, Ann Arbor
• 02:15pm - 03:30pm ET

  Rising Utilization of Hyperbaric Oxygen Therapy for Radiation-Related Genitourinary Injury: A 10-Year Institutional Analysis

  Speaker: Sasha Ebrahimi, MD, PhD - UCLA Radiation Oncology, Los Angeles
• 02:15pm - 03:30pm ET

  Clinical Outcomes and Toxicities of Proton Beam Therapy for Testicular Seminoma: Results from the Proton Collaborative Group Prospective Registry

  Speaker: Lifei Zhu, MD, PhD - Montefiore Medical Center/Albert Einstein College of Medicine, Bronx
• 02:15pm - 03:30pm ET

  Understanding Demographic and Geographic Trends in DECIPHER Genomic Scores

  Speaker: Mathew Lin, BS - Dartmouth Geisel School of Medicine, Lebanon
• 02:15pm - 03:30pm ET

  Therapeutic Ratio of Seminal Vesicle Sparing vs. Inclusion in Prostate Stereotactic Body Radiation Therapy: A Propensity Score-Matched Competing Risks Analysis

  Speaker: Van Ton Tran, MD, MS - Department of Therapeutic Radiology, University of Yamanashi, Japan, Chuo-shi
• 02:15pm - 03:30pm ET

  Trimodality Therapy for Muscle-Invasive Bladder Cancer: Two Ways to the Same Target

  Speaker: Wojciech Majewski, MD, PhD - Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice
• 02:15pm - 03:30pm ET

  Safety and Clinical Outcomes of Combining Radiotherapy with Lutetium-177-PSMA Therapy in Metastatic Castrate-Resistant Prostate Cancer

  Speaker: Patrick Carriere, MD, PhD - MD Anderson Cancer Center, Houston
• 02:15pm - 03:30pm ET

  Preliminary Results of a Prospective Study Investigating the Relationship between Change in PET Signal and Changes in Pathology Pre- to Mid-Treatment In High Risk Prostate Cancer

  Speaker: Daniela Duenas, BS - University of Wisconsin School of Medicine and Public Health, Madison
• 02:15pm - 03:30pm ET

  Magnetic Resonance Imaging (MRI) Radiomics that Predicts the Treatment Outcome in a Phase 2 Trial of Ra-223 Combined with Stereotactic Body Radiation Therapy and Androgen Deprivation Therapy (ADT) for Oligometastatic Castrate Sensitive Prostate Cancer

  Speaker: Kun Qing, PhD - City of Hope Comprehensive Cancer Center, Duarte
• 02:15pm - 03:30pm ET

  Comparable Early Outcomes With Moderately Hypofractionated Versus Conventional Secondary Radiotherapy After Prostatectomy

  Speaker: Kendall Garrett, MD, BS - Case Western Reserve School of Medicine, Cleveland
• 02:15pm - 03:30pm ET

  MR-Guided Stereotactic Radiotherapy for Oligometastatic Prostate Cancer: Toward Optimal Patient Selection

  Speaker: Levi Burns, MD, MS - University of Toronto, Toronto
• 02:15pm - 03:30pm ET

  Optimizing Perirectal Spacer Use: Risk Factors for Rectal Toxicity and Bowel Quality of Life after Hypofractionated Radiation Therapy for Prostate Cancer

  Speaker: Mira Patel, MD, BS - UChicago Medicine, Chicago
• 02:15pm - 03:30pm ET

  Clinical Impact and Concordance of Three Advanced Risk Stratification Tools for ADT Decision-Making In Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer

  Speaker: Shera Feinstein, MD - UC Irvine Health, Orange
• 02:15pm - 03:30pm ET

  Evaluating Reduced PTV Margins Enabled by MR-Linac Comprehensive Motion Management (CMM) in Prostate Stereotactic Radiotherapy (SBRT): Dosimetric and Clinical Implications

  Speaker: Ho Lam Lisa Chan, CMD, RT - Hong Kong Sanatorium and Hospital, Hong Kong
• 02:15pm - 03:30pm ET

  Impact of 68 Ga-PSMA PET/CT Staging on Metastasis-Free and Cancer-Specific Survival after Definitive Radiotherapy for High-Risk Prostate Cancer

  Speaker: Cem Onal, MD - Baskent University Faculty of Medicine, Department of Radiation Oncology, Ankara, Turkey, ankara
• 02:15pm - 03:30pm ET

  Late Genitourinary Toxicity after Definitive Radiotherapy with or without Simultaneous Integrated Boost In Post-TURP Prostate Cancer: A Competing-Risk Study

  Speaker: Huseyin Cem Onal, MD - Baskent University Faculty of Medicine, Adana
• 02:15pm - 03:30pm ET

  Impact of Extended Pelvic Lymph Node Dissection on Outcomes in High-Risk Prostate Cancer Patients Receiving Postoperative Pelvic Radiotherapy: A Secondary Analysis of a Prospective Study

  Speaker: Xue-Ying Ren, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  Modulation of Anti-Tumor Immune Responses by PD-1-laIL2 Sequentially Combined with Radiotherapy in a Metastatic Prostate Cancer Model

  Speaker: Huizhu Chen, MD - Peking University First Hospital, Beijing
• 02:15pm - 03:30pm ET

  Effect of PSMA PET/CT Image Review as a Visual Navigation Aid in a Vulnerable Prostate Cancer Population

  Speaker: Kritika Subramanian, MD, MS - Montefiore Medical Center/Albert Einstein College of Medicine, Bronx
• 02:15pm - 03:30pm ET

  The Evolution of Prostate Cancer Presentation

  Speaker: Jilcha Feyisa, MD, MPH - Dartmouth-Hitchcock Medical Center, Lebanon
• 02:15pm - 03:30pm ET

  Comparison of Urinary Toxicity in Prostate Cancer Patients Undergoing External Beam Radiation Therapy With High-Dose vs. Low-Dose Brachytherapy Boost

  Speaker: Catherine Drovetsky, BS - University of Maryland School of Medicine, Baltimore
• 02:15pm - 03:30pm ET

  A Single Institution Experience Comparing Outcomes of Muscle Invasive Bladder Cancer of Urothelial or Alternative Histology Treated with Trimodality Therapy

  Speaker: Celina Chiodo, MD, MS - Moffitt Cancer Center, Tampa
• 02:15pm - 03:30pm ET

  The Role of Stereotactic Body Radiotherapy in Oligoprogressive Renal Cell Carcinoma: A Site-Specific Analysis of the Phase II RADIANT Trial

  Speaker: Neelabh Rastogi, MD - University of Toronto, Toronto
• 02:15pm - 03:30pm ET

  Prognostic Impact of Grade Group Discordance between MRI-Targeted and Systematic Biopsy Cores in Localized Prostate Cancer

  Speaker: Hyo Jin Ryu, DO - University of California, San Francisco, San Francisco
• 02:15pm - 03:30pm ET

  Physician and Patient Reported Outcomes Following Contemporary Image-Guided Intensity Modulated Proton Therapy for Prostate Cancer: Results from the Prospective PRO-Cube Study

  Speaker: Srinivas Chilukuri, MD, MBBS - Apollo Proton Cancer Centre, Chennai
• 02:15pm - 03:30pm ET

  Dosimetric Correlates of Long-Term Quality of Life In a Randomized Trial of Prostate Radiation Therapy with and without a Hydrogel Spacer

  Speaker: Abdallah Mohamed, MD, PhD - Baylor College of Medicine, Houston
• 02:15pm - 03:30pm ET

  Dosimetric Assessment of ¹77Lu-PSMA-617 and SBRT In Locally Advanced Prostate Cancer: Interim Dosimetry of the STARLiT Trial

  Speaker: Qing Li, MD, PhD - Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland
• 02:15pm - 03:30pm ET

  PSA Kinetics and Functional MRI as Complementary Biomarkers of Response after MR-Guided Focal Boost Radiotherapy for High-Risk Prostate Cancer

  Speaker: Haruo Inokuchi, MD, PhD - osaka metropolitan university, Osaka-city
• 02:15pm - 03:30pm ET

  Low Acute Toxicity with Online CT-Based Adaptive Radiation Therapy for Prostate Cancer

  Speaker: Paul Ramia, MD - Cleveland Clinic Abu Dhabi, Abu Dhabi
• 02:15pm - 03:30pm ET

  Deep Learning Auto-Segmentation of the Internal Pudendal Artery on CT: Dosimetric Validation Against MRI-Informed Ground Truth Contours

  Speaker: Omar Awad, MD, MS - Baylor College of Medicine, Houston
• 02:15pm - 03:30pm ET

  Benchmarking Multimodal AI-Predicted Metastasis and Prostate Cancer-Specific Mortality Risk Against STAR-CAP: A 20,000-Patient Commercial Experience

  Speaker: Daniel Spratt, MD - University Hospitals Seidman Cancer Center, Case Western Reserve University, Beachwood
• 02:15pm - 03:30pm ET

  A Phase II Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The Miami MAPS Trial

  Speaker: David Lee, MD - Sylvester Comprehensive Cancer Center, University of Miami, Miami
• 02:15pm - 03:30pm ET

  Local Radiotherapy and ADT Monotherapy for Low-Volume mHSPC: Real-World Outcomes in the Era of PSMA PET-CT Staging

  Speaker: Yuen Hang Lau, MBBS - Queen Elizabeth Hospital, Hong Kong
• 02:15pm - 03:30pm ET

  Prevalence and Risk Factors for Food Insecurity among Patients Receiving Radiation Therapy

  Speaker: John Pottow, - Pioneer High School, Ann Arbor
• 02:15pm - 03:30pm ET

  Redefining Pediatric Radiation Oncology Training in Resource-Constrained Settings: The PedROC Virtual Education Model

  Speaker: Adedayo Joseph, MD - Lagos University Teaching Hospital, Lagos
• 02:15pm - 03:30pm ET

  Timeliness of In-Patient Radiation Therapy: An Informatics Care Pathway Interval Analysis of Hospital Length of Stay in an Integrated Health System

  Speaker: Pranshu Mohindra, MD, MMM, FABS - University Hospitals Cleveland Medical Center/ Seidman Cancer Center, Cleveland, OH, Cleveland
• 02:15pm - 03:30pm ET

  Delay vs. Non-Receipt of Post-Craniotomy Radiation Therapy: Association of Facility Availability, Proximity, and Social Vulnerability

  Speaker: Peter Orio, DO, MS, FASTRO - Dana-Farber Cancer Institute , Boston
• 02:15pm - 03:30pm ET

  Failure to Rescue in Radiation Enteritis: National Patterns of GI Management, Hospital-Level Variation, and Socioeconomic Disparities

  Speaker: Jeril Lasington, MD, MS, MBBS - New York Medical College at St.Mary's and St. Clare's, Denville
• 02:15pm - 03:30pm ET

  Patient Perspectives on the Impact of Survivor-Narrative Education Videos in Botswanan Gynecological Cancer Care

  Speaker: Sruthi Prabha Suresh, BS - UT Southwestern Medical Center, Dallas
• 02:15pm - 03:30pm ET

  The Burden of Cervical Cancer in Patient over 65: Identifying Systematic Failure and the Case for Extended Screening Guidelines

  Speaker: Anna Likhacheva, MD, MPH - Sutter Medical Group, Sacramento
• 02:15pm - 03:30pm ET

  Radiation Oncology Physician Workforce Populations: A Snapshot from the 2025 ASTRO Annual Member Survey

  Speaker: Joseph Salama, MD, FASTRO - Duke University Medical Center, Durham
• 02:15pm - 03:30pm ET

  Academic and Geographic Employment Outcomes for Graduating Residents in Radiation Oncology: 2023 to 2024

  Speaker: Nicholas Murphy, MD - Mount Sinai Hospital, New York
• 02:15pm - 03:30pm ET

  Clinical and Access-Related Determinants of Curative-Intent Radiation Therapy Treatment Termination in Head and Neck Cancer

  Speaker: Kunika Chahal, MD, MPH - Northwell Health Cancer Institute, Lake Success
• 02:15pm - 03:30pm ET

  Prior Primary Care Utilization and Racial Disparities in Breast Cancer Metastatic Presentation and Mortality

  Speaker: Sakshith Reddy Chintala, MS - University of California San Diego, La Jolla
• 02:15pm - 03:30pm ET

  Sociodemographic Factors Informing Overall Survival in Patients Treated with SBRT

  Speaker: Tushar Joshi, BS - University of North Carolina at Chapel Hill, Chapel Hill
• 02:15pm - 03:30pm ET

  The Active U.S. Radiation Oncology Workforce: A Medicare Billing-Based Analysis, 2013-2023

  Speaker: Anna Skakodub, MD - Mount Sinai, New York
• 02:15pm - 03:30pm ET

  The Influence of Payer Type vs. Community Characteristics in Shaping Realized Access to Proton Therapy

  Speaker: Peter Orio, DO, MS, FASTRO - Dana-Farber Cancer Institute , Boston
• 02:15pm - 03:30pm ET

  A Bibliometric Analysis of Scholarly Output by the Society for Women in Radiation Oncology

  Speaker: Raksha Narasimhan, BS - University of Miami Miller School of Medicine, Miami
• 02:15pm - 03:30pm ET

  Progressive Institutional Standardization of VMAT for Palliative Radiotherapy in a Low- and Middle-Income Country: A 5-Year Time-Series Analysis

  Speaker: Brena Souza, MD - Oncologia Dor, Rio de Janeiro
• 02:15pm - 03:30pm ET

  Malnutrition Screening Gaps and Nutritional Intervention Disparities in GI Cancer Patients Receiving Radiation Therapy: A National Inpatient Analysis

  Speaker: Jeril Lasington, MD, MS, MBBS - New York Medical College at St.Mary's and St. Clare's, Denville
• 02:15pm - 03:30pm ET

  Building an Age-Friendly Radiation Oncology Program: A Mobility-First 4Ms Roadmap

  Speaker: Alexander Qian, MD - University of California San Francisco, San Francisco
• 02:15pm - 03:30pm ET

  Inequity for the Territory: Disparity in Access to Proton Therapy for Australia's Most Unique Population

  Speaker: Hugh Schievenin, MBBS, MBBS - Royal Adelaide Hospital - South Australia Health, Adelaide`
• 02:15pm - 03:30pm ET

  Marital Status and IDH-Wildtype Glioblastoma: A Propensity-Matched Analysis of Treatment Receipt and 90-Day Mortality

  Speaker: Miriam Lane, MD - University of California Los Angeles, Los Angeles
• 02:15pm - 03:30pm ET

  Gender Representation in Radiation Oncology Residency Training in Mexico: A National Multicenter Census (2022-2025)

  Speaker: Fernanda Rivera, MD - Instituto Mexicano del Seguro Social, Guadalajara
• 02:15pm - 03:30pm ET

  Medicare Advantage Representation at U.S. Proton Therapy Centers Relative to Catchment-Weighted Benchmarks

  Speaker: Peter Orio, DO, MS, FASTRO - Dana-Farber Cancer Institute , Boston
• 02:15pm - 03:30pm ET

  Prognostic and Therapeutic Significance of Common Iliac Lymph Node Involvement in Cervical Cancer in the Era of EMBRACE and INTERLACE

  Speaker: Krithikaa Sekar, MD, MBBS - Healthcare Global Enterprises Ltd., Bangalore
• 02:15pm - 03:30pm ET

  Long-Term Results of Stereotactic Body Radiotherapy Boost In Patients with Cervical Cancer Ineligible for Intracavitary Brachytherapy: Secondary Analysis of a Phase I/II Study

  Speaker: Kei Ito, MD, PhD - Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku
• 02:15pm - 03:30pm ET

  Prognostic Value of a Partial Metabolic Response on Post-Treatment PET/CT in Locally Advanced Cervical Cancer

  Speaker: Paige Hinman, BS - University of Virginia School of Medicine, Charlottesville
• 02:15pm - 03:30pm ET

  Molecular Classification-Guided Adjuvant Therapy and the Prognosis for Early-Stage Endometrial Carcinoma: Evidence from a Population-Based Cohort Study by Using IPTW Analysis

  Speaker: Lingxia Xin, MD - eking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Beijing
• 02:15pm - 03:30pm ET

  Is the a/ß of Cervical Cancer Low? New Clinical Estimates of the a/ß of Cervical Cancer

  Speaker: Cameron Thayer-Freeman, PhD, MS - University of Kentucky, Lexington
• 02:15pm - 03:30pm ET

  Cervicovaginal Bacterial Microbiome Remodeling after Brachytherapy in Patients with Locally Advanced Cervical Cancer Patient Treated with Chemoradiation with or without Therapeutic HPV Vaccine

  Speaker: Tissana Prasartseree, MD - Siriraj Hospital Mahidol University, Bangkok
• 02:15pm - 03:30pm ET

  Improving Radiotherapy-Induced Gastrointestinal Toxicity Detection: ALERT-B in Botswana

  Speaker: Caroline Kernell, MD, BS - Hospital of the University of Pennsylvania, Philadelphia
• 02:15pm - 03:30pm ET

  Quality Assurance Analysis of Staging and Radiotherapy in OUTBACK Trial: Impact of Protocol Permitted Variations on Clinical Outcomes in Locally Advanced Cervical Cancer

  Speaker: Ming Yin Lin, MD, MBBS - Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne
• 02:15pm - 03:30pm ET

  MCT Inhibition Targets Cervical Cancer in Lactate Enriched Microenvironments

  Speaker: David Lo, BS - University of Texas MD Anderson Cancer Center, Houston
• 02:15pm - 03:30pm ET

  Exploring the Molecular Classification-Based Personalized Treatment Decision-Makings in FIGO Stage I-III Endometrial Carcinoma after Surgery

  Speaker: Lingxia Xin, MD - eking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Beijing
• 02:15pm - 03:30pm ET

  Improving Outcomes in Bulky, Eccentric Locally Advanced Cervical Cancer: A Prospective Study of VMAT-Based Simultaneous Integrated Boost Radiotherapy for Lateral Para-cervical High-Tumor-Burden Region

  Speaker: Yuyan Gao, MD, PhD - Beijing Luhe Hospital, Beijing
• 02:15pm - 03:30pm ET

  Outcomes of a Transrectal Ultrasound-Guided Real-Time Adaptive Brachytherapy Program for Locally Advanced Cervical Cancer: A Prospective Analysis of 61 Consecutive Patients

  Speaker: Urvashi Gupta, MD, MBBS - Amrita Institute of Medical Sciences and Research Centre, Faridabad
• 02:15pm - 03:30pm ET

  Molecular Subtypes in Patients with Recurrent Endometrial Cancer Treated with Definitive Radiation

  Speaker: Lauren Bendesky, MD, MBA - University of California San Francisco, San Francisco
• 02:15pm - 03:30pm ET

  Integrating HPV ctDNA Dynamics and Tumor Geometry to Guide Selection of 3D-Printed Applicators in Cervical Cancer Brachytherapy: Development and External Validation of a Prognostic Model

  Speaker: Wiwatchai Sittiwong, MD - Siriraj Hospital Mahidol University, Bangkok
• 02:15pm - 03:30pm ET

  Allostatic Load as a Predictor of Outcomes in Cervical Cancer Patients Receiving Definitive Chemoradiotherapy

  Speaker: Devon Dietrich, BA - University of Chicago Pritzker School of Medicine, Chicago
• 02:15pm - 03:30pm ET

  Impact of Molecular Classification on Adjuvant Treatment Decisions in Endometrial Cancer: A Comparative Analysis

  Speaker: Barbara Helena Zobec Logar, MD, PhD, MS - Institute of Oncology Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana
• 02:15pm - 03:30pm ET

  High-Risk CTV Geometric Features and Spatial Relationships to Organs at Risk as Determinants of Dosimetric Benefit with Combined Intracavitary/Interstitial Brachytherapy in Cervical Cancer

  Speaker: Dima Soultan, MS - University of Kansas Cancer Center, Kansas City
• 02:15pm - 03:30pm ET

  Pelvic Bone Marrow Dosimetry and Peripheral T-Cell Subset Dynamics After Cervical Cancer Radiotherapy

  Speaker: Wenxin He, MD, PhD - Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
• 02:15pm - 03:30pm ET

  Updates on Prospective Phase III Trial of Standard of Care Therapy with/without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer

  Speaker: Yong Bae Kim, MD - Yonsei Cancer Center, Yonsei University College of Medicine, Seoul
• 02:15pm - 03:30pm ET

  Interfraction Motion of the Retroverted Uterus during Radiotherapy for Cervical Cancer

  Speaker: Elena Riggenbach, MD - Radiation Medicine Program, University Health Network and Princess Margaret Cancer Centre, Toronto
• 02:15pm - 03:30pm ET

  Individualized Radiosensitivity-Guided Radiation Therapy for Cervical Cancer

  Speaker: Wenbin Gao, PhD - Cancer Hospital of Shandong First Medical University, Shandong
• 02:15pm - 03:30pm ET

  Salvage Radiation Therapy for Recurrent or Oligometastatic Ovarian Cancer

  Speaker: Audrey Goodman, BS - UCI School of Medicine, Orange
• 02:15pm - 03:30pm ET

  Evaluation of AI-Generated Contours for MRI-Based Gynecological HDR Brachytherapy

  Speaker: Hayeon Kim, PhD - Magee Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh
• 02:15pm - 03:30pm ET

  Quantification of Three-Dimensional Morphometric Parameters of the High-Risk Clinical Target Volume before and after Brachytherapy Applicator Placement Using MRI for Patients with Cervical Cancer

  Speaker: Dylan Ross, MD - Johns Hopkins Hospital, Baltimore
• 02:15pm - 03:30pm ET

  Lateral Differences in Transposed Ovary Motion: A Large-Scale FBCT Analysis for Personalized PRV Margins in Cervical Cancer Radiotherapy

  Speaker: Xiaolong Cheng, MD - Zhejiang Cancer Hospital, Hangzhou
• 02:15pm - 03:30pm ET

  Development of Cylinder Applicators for Intensity-Modulated Brachytherapy In Vagnial Cancers

  Speaker: Chanil Jeon, PhD - National Cancer Center, Korea, Goyang
• 02:15pm - 03:30pm ET

  CRAIN: A Phase Ib Tite-CRM Dose Escalation Study of Tolinapant with Chemoradiotherapy for Locally Advanced Cervical Cancer Including Clinical and Translational Endpoints

  Speaker: Peter Hoskin, MD - Mount Vernon Hospital and University of Manchester, Northwood
• 02:15pm - 03:30pm ET

  First Large-Scale Analysis of Transposed Ovary Motion Using High-Resolution FBCT from a Chinese-Developed Integrated CT-Linear Accelerator: PRV Margin Optimization for Ovarian-Sparing Cervical Cancer Radiotherapy

  Speaker: Xiaolong Cheng, MD - Zhejiang Cancer Hospital, Hangzhou
• 02:15pm - 03:30pm ET

  Association Between Organ Puncture and Acute Toxicity Following CT-Guided Interstitial HDR Brachytherapy for Gynecologic Malignancies: A Retrospective Cohort Study

  Speaker: Salma Amin, MPH - Meharry Medical College, Nashville
• 02:15pm - 03:30pm ET

  CT-guided and MR-guided Adaptive Radiotherapy for Gynecological SBRT Treatments: A Dosimetry and Workflow Analysis

  Speaker: Dishane Luximon, PhD - University of California Los Angeles, Los Angeles
• 02:15pm - 03:30pm ET

  Impact of the 2023 ASTRO Endometrial Clinical Practice Guidelines on a Single Institution's Use of Adjuvant Therapy for Early-Stage Disease

  Speaker: Sophia Slankard, BS - University of California, Irvine, Orange
• 02:15pm - 03:30pm ET

  Clinical Characteristics and Prognostic Nomogram for Different Metastatic Patterns in Cervical Cancer

  Speaker: Wenjuan Chen, - Department of Radiotherapy, Gynecology, Clinical Oncology School of Fujian Medical University, FujianCancer Hospital, Fuzhou, China, Fuzhou
• 02:15pm - 03:30pm ET

  Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Locally Advanced Cervical Squamous Cell Carcinoma (NOTABLE-306): A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial

  Speaker: Shuhua Wei, PhD - Peking University Third Hospital, Beijing
• 02:15pm - 03:30pm ET

  8 Mm and 3 Mm: The Optimal PTV Margins for Uterine and Cervical Ctvs In Online Adaptive Radiotherapy

  Speaker: Xinyue Gong, MD - Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing
• 02:15pm - 03:30pm ET

  Adjuvant Therapy Sequencing for Endometrial Cancer in the Era of Molecular Classification

  Speaker: Enes Atici, MD - University of Kentucky, Lexington
• 02:15pm - 03:30pm ET

  Preoperative Radiation Therapy in the Management of Surgically Inoperable Endometrial Cancer

  Speaker: Sayeh Fattahi, MD - Harvard Radiation Oncology Program, Boston
• 02:15pm - 03:30pm ET

  Trends in Aggressive End-of-Life Care for Metastatic Cervical Cancer

  Speaker: Andrew Puthran, BS - Indiana University School of Medicine, Indianapolis
• 02:15pm - 03:30pm ET

  PET Based Biopsy Triage Following Definitive Brachytherapy in Cervical Cancer

  Speaker: Ryan Zitter, MD, MSc - University of Chicago, Chicago
• 02:15pm - 03:30pm ET

  Pelvic Radiation and Female Sexual Health: A Dosimetric Feasibility Study of the Bulboclitoris as an Organ-at-Risk in Gynecologic Cancers

  Speaker: Lamees El Nihum, MD, MEng - Fox Chase Cancer Center, Philadelphia
• 02:15pm - 03:30pm ET

  Isolated Tumor Cells and Impact on Recurrence in Endometrioid Endometrial Adenocarcinoma

  Speaker: Jayne-Norah Ntambi, MD - Tufts Medical Center, Boston
• 02:15pm - 03:30pm ET

  What is the Value of Concurrent Chemoradiation for Vaginal Recurrence of Endometrial Cancer in the Setting of Prior Brachytherapy?

  Speaker: Catherine Medina, BS - University of Pittsburgh School of Medicine, Pittsburgh
• 02:15pm - 03:30pm ET

  Definitive Radiotherapy with Systematic Therapy: Curative-Intent Treatment for Oligometastatic Cervical Cancer: A Single-Arm, Phase 2 Trial

  Speaker: Jing Liu, MD, PhD - , Jinan
• 02:15pm - 03:30pm ET

  Pelvic Radiation Therapy in Patients Aged 80 and Older: Predictive Factors of Treatment Completion

  Speaker: Lily Ottensoser, MD - Northwell Health, Lake Success
• 02:15pm - 03:30pm ET

  Locoregional Radiotherapy Dose as a Prognostic Factor in Single Site Metastatic Endometrial Cancer

  Speaker: Madeline Flanagan, MD - Baylor College of Medicine, Houston
• 02:15pm - 03:30pm ET

  Chemoradiotherapy Compliance and Toxicities Among Cervical Cancer Patients in a High HIV-Prevalence Population

  Speaker: Taylor Avery, BS - Cooper Medical School of Rowan University, Camden
• 02:15pm - 03:30pm ET

  Clinical Implantation of Adaptive Radiation Treatment using MR-guided Linac for Salvage Radiation Treatment of Gynecological Malignancies

  Speaker: Aishah AlQaderi, MBBS - University of Toronto, Toronto
• 02:15pm - 03:30pm ET

  Time- and Response-Guided Adapt-on-Demand Radiation Therapy for Cervical Cancer: Optimal Timing and Dosimetric Benefit from a Prospective Registry

  Speaker: Elizabeth Park, PhD - University of Texas Southwestern Medical Center at Dallas, Dallas
• 02:15pm - 03:30pm ET

  Subsystem Level Analysis of Allostatic Load in Locally Advanced Cervical Cancer Patients Treated with Definitive Chemoradiation

  Speaker: Shalina Chithriki, BS - University of Miami - Sylvester Cancer Center, Coral Gables
• 02:15pm - 03:30pm ET

  A Patient Vulnerability Score Predicts Radiation Treatment Modification and Survival in Gynecologic External Beam Radiation Therapy

  Speaker: Cynthia Martucci, BS - Zucker School of Medicine at Hofstra/Northwell, New Hyde Park
• 02:15pm - 03:30pm ET

  Dosimetric Impact of MRI-Based Planning Plus Multichannel Cylinder for Vaginal Cuff Brachytherapy

  Speaker: Colton Ladbury, MD - City of Hope National Medical Center, Duarte
• 02:15pm - 03:30pm ET

  The Value of Optimized CT Guided Brachytherapy Workflow for Cervical Cancer

  Speaker: Xiaojing Yang, MD, PhD - Shanghai Sixth People's Hospital, Shanghai
• 02:15pm - 03:30pm ET

  Association Between Survival and Dynamic Changes in Peripheral Lymphocyte Count During Radiotherapy in Older Patients with Locally Advanced Cervical Cancer

  Speaker: Takeshi Fujisawa, MD, PhD - University of Tsukuba, Tsukuba City 305-8575
• 02:15pm - 03:30pm ET

  Prognostic Factors in Stage I-II High-Risk Endometrial Cancer: Including the Role of Inflammatory Marker

  Speaker: Min Kyun Ko, MD - Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul
• 02:15pm - 03:30pm ET

  Locally Advanced Cervical Cancer Treated with Definitive Chemo and Radiation with Brachytherapy Boost: Dosimetry Comparison of Multi Plan with Single Plan Brachytherapy Approach

  Speaker: Suvidya Pachigolla, MD, MS, BS - Northwestern Feinberg School of Medicine, Chicago
• 02:15pm - 03:30pm ET

  Can Treatment Response to Radiation In Non-Operable Endometrial Cancer Predict Outcomes?

  Speaker: Sophia Kim-Wang, MD, PhD - University of Chicago, Chicago
• 02:15pm - 03:30pm ET

  Impact of Age on Chemotherapy Dose in Patients with Node Negative Cervical Cancer Treated with Chemoradiotherapy: A Prospective Observational Study

  Speaker: John Mathew, MD - Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry
• 02:15pm - 03:30pm ET

  Evaluation of Proton Beam Radiotherapy In Ovarian Cancer: Analysis of the Multicenter Proton Collaborative Group Prospective Registry

  Speaker: Ranjani Padmanabhan, MD - New York Presbyterian Brooklyn Methodist Hospital, Brooklyn
• 02:15pm - 03:30pm ET

  Single-Cell Analysis Identifies SDC1 as a Key Mediator Bridging Extracellular Matrix Stiffness and Radioresistance in Recurrence of Cervical Cancer

  Speaker: Feidi Sun, - The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
• 02:15pm - 03:30pm ET

  Can Open-Source Artificial Intelligence Reduce Disparities In Radiation Oncology? A Pilot Auto-Segmentation Study In a High-Volume Public Center for Female Pelvic Malignancies

  Speaker: Felipe Castro, MD, DRCPSC - Instituto Nacional de Enfermedades Neoplasicas, Lima
• 02:15pm - 03:30pm ET

  A Dosimetric Feasibility of UPFRONT Single-Fraction Brachy-like MR-Guided SBRT Followed By Chemoradiation and Brachytherapy as a Radical Re-Sequencing Therapy to Boost Radio-Immunopotentiation In Cervical Cancer

  Speaker: Tissana Prasartseree, MD - Siriraj Hospital Mahidol University, Bangkok
• 02:15pm - 03:30pm ET

  Domain-Specific Self-Supervised Pre-Training on Large-Scale MRI Data Enhances Organs-at-Risk Segmentation for MR-Linac Adaptive Radiotherapy In Cervical Cancer

  Speaker: Cong Wang, MD - Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan
• 02:15pm - 03:30pm ET

  The Prognosis of HPV Infection in Vulvar Cancer Patients

  Speaker: Sadhana Pani, BS - Johns Hopkins University School of Medicine, Baltimore
• 02:15pm - 03:30pm ET

  Bladder Volume Consistency during 5-Fraction Adaptive Adjuvant SBRT for Gynecologic Cancers: Institutional Ultrasound-Guided Filling Protocol In Patients Treated on the HERA Trial

  Speaker: Rojine Ariani, MD, MS - UCLA David Geffen School of Medicine/UCLA Medical Center, Los Angeles
• 02:15pm - 03:30pm ET

  Cervical Cancer Management and Outcomes in a Geriatric Patient Population

  Speaker: Rie Maeda, BS - Cleveland Clinic Lerner College of Medicine, Cleveland
• 02:15pm - 03:30pm ET

  A Retrospective Analysis of Simultaneous Integrated Boost (SIB) to Close or Positive Parametrial Margins in Adjuvant Pelvic Radiotherapy for Endometrial Cancer

  Speaker: Zuhayr Yakub, MD, BHSc - McMaster University, Hamilton
• 02:15pm - 03:30pm ET

  Impact of Laparoscopic Surgeries Prior to Definitive Chemoradiation for Cervical Cancer on Risk of Cancer Progression: A U.S. Healthcare Claims Database Analysis

  Speaker: Emily Smith, MD - Stanford Health Care, Stanford
• 02:15pm - 03:30pm ET

  A Prospective Study of FDG-PET based Simultaneous Integrated Boost for Node Positive Cervical Cancer

  Speaker: Ritusha Mishra, MD, MBBS, DNB - Institute of Medical Sciences, Varanasi
• 02:15pm - 03:30pm ET

  Clinical Outcomes Following Definitive Chemoradiation In Patients with Glassy-Cell Cervical Carcinoma: A Single Institution Retrospective Analysis

  Speaker: Sabi Shrestha, MD - University of Texas Health Science Center San Antonio, San Antonio
• 02:15pm - 03:30pm ET

  HR-CTV Volume as a Predictor of Organ at Risk Dose Constraint Achievement in Image Guided Adaptive Brachytherapy for Cervical Cancer

  Speaker: Belal Abousaida, MD, PhD, MS - KUMC Department of Radiation Oncology, Kansas
• 02:15pm - 03:30pm ET

  Prospective Validation of a CT-Based Radiomics Nomogram for the Early Prediction of Malnutrition in Stage IB-IIA Cervical Cancer Patients Receiving Postoperative (Chemo)radiotherapy

  Speaker: Tao Song, MD - Zhejiang Provincial People's Hospital, Hangzhou
• 02:15pm - 03:30pm ET

  Persistent Rural-Urban Disparities in Lung Cancer Survival within an Academic Treatment Setting: Implications for Equitable Radiation Oncology Delivery

  Speaker: Dema Sami, BA - University of Kentucky College of Medicine, Lexington
• 02:15pm - 03:30pm ET

  Prospective Phase 1 Clinical Trial of CBCT-Guided Adaptive SBRT to the Prostate and Pelvic Nodes with Simultaneous Integrated Boost to the MR-Detected Nodule for Patients with High-Risk and Unfavorable Intermediate-Risk Prostate Cancer

  Speaker: Vladislav Sviderskiy, MD, PhD - Washington University School of Medicine in St. Louis, St. Louis
• 02:15pm - 03:30pm ET

  Prospective Study of Rectal Spacer Application with Adaptive MR-Guided SBRT in cT3a-T3b Prostate Cancer

  Speaker: Darren Poon, MD - The Hong Kong Sanatorium & Hospital, Hong Kong
• 02:15pm - 03:30pm ET

  Stereotactic Body Radiotherapy (SBRT) Re-Irradiation for Local Recurrence of Prostate Cancer: A Multi-Institutional Experience in Uruguay

  Speaker: Estefania Melean, RT - Clinica COR, Montevideo
• 02:15pm - 03:30pm ET

  Real-World Outcomes of [177 Lu]Lu-PSMA-617 (177 Lu-PSMA-617) Treatment Extension in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): A PRostatE Cancer dISease observatION (PRECISION) Database Analysis

  Speaker: Xiao Wei, MD, MAS - Dana-Farber Cancer Institute, Boston
• 02:15pm - 03:30pm ET

  Impact of Prostate-Specific Membrane Antigen Scans on Treatment Decision-Making in Patients with Metastatic Prostate Cancer in Clinical Practice: A PRostatE Cancer dISease observatION (PRECISION) Database Analysis

  Speaker: Xiao Wei, MD, MAS - Dana-Farber Cancer Institute, Boston
• 02:15pm - 03:30pm ET

  Stereotactic Body Radiotherapy (SBRT) Boost on MRLINAC in Patients of Carcinoma Cervix after External Beam Radiotherapy (EBRT) who are Ineligible for High Dose Rate Brachytherapy- Early Experience at a Single Institution

  Speaker: Swarupa Mitra, MD, MBA, MBBS - Rajiv Gandhi Cancer Institute & Research Centre, Delhi
• 02:15pm - 03:30pm ET

  Multicohort Validation of Genetic Variants Associated with Radiation-Induced Hematuria in Prostate Cancer Patients

  Speaker: Sarah Kerns, PhD, MPH - Medical College of Wisconsin, Milwaukee
• 02:15pm - 03:30pm ET

  FocaSaBra: A Prospective Phase II Trial of Focal Salvage Brachytherapy for Locally Recurrent Prostate Cancer after Radiotherapy

  Speaker: Adam Kluska, MD, PhD - Greater Poland Cancer Center, Poznan
• 02:15pm - 03:30pm ET

  Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer after Radiotherapy: Long-Term Outcomes and Predictive Factors

  Speaker: Adam Kluska, MD, PhD - Greater Poland Cancer Center, Poznan
• 02:15pm - 03:30pm ET

  Impact of Clinical Factors on 18 F-Piflufolastat and 18 F-Flotufolastat Detection Rates in Patients with Recurrent Prostate Cancer Post-Prostatectomy: Results from an Intra-Patient Head-to-Head Study

  Speaker: Todd Cohen, MD - Blue Earth Diagnostics, Inc., Needham
• 02:15pm - 03:30pm ET

  Knowledge and Opinions on Trauma-Informed Care in Radiation Oncologists and Trainees Involved in Gynecologic Brachytherapy in Canada

  Speaker: Talar Derashodian, MD - Cross Cancer Institute, Edmonton
• 02:15pm - 03:30pm ET

  SOLACE: A Phase 1 Pharmacokinetic, Dosimetry, Safety and Dose Optimization Study for a Single Dose of 153 Sm-DOTMP to Treat Metastatic Bone Pain

  Speaker: Ebrahim Delpassand, MD - Excel Diagnostics and Nuclear Oncology Center, Houston
• 02:15pm - 03:30pm ET

  Stereotactic Magnetic Resonance-Guided Adaptive Radiotherapy for Prostate Cancer from Prospective Phase II Trial: Prostate vs. Prostate, pElvis and Metastases (SMART-P vs. SMART-PEM)

  Speaker: Ning-Ning Lu, MD - National Cancer Center, Beijing
• 02:15pm - 03:30pm ET

  Standardized Bowel Preparation for Pelvic Radiation Therapy Patients

  Speaker: Zayd Jastaniah, MD, MBBS - King Abdulaziz University, Jeddah
• 02:15pm - 03:30pm ET

  Dosimetric and Mammographic Predictors of Breast Lymphedema after Breast-Conserving Therapy

  Speaker: Isaac Lasko, MD - Loyola University Medical Center, Maywood
• 02:15pm - 03:30pm ET

  Clinical Validation of Dose Regimen Generalized AI Prostate SBRT Plans: Dosimetric Comparison, Blinded Physician Review, and Deliverability Assessment

  Speaker: Nayoon Lee, BA - University of Pennsylvania, Philadelphia
• 02:15pm - 03:30pm ET

  Delivered Dosimetry during Post-Prostatectomy Prostate Bed SBRT with MR-Guided Versus CT-Guided Radiotherapy

  Speaker: Esther Yu, MD - UCLA David Geffen School of Medicine/UCLA Medical Center, Los Angeles
• 02:15pm - 03:30pm ET

  Association of 22-Gene Genomic Classifier with ADT Use with Secondary Radiotherapy: A National Real-World Analysis

  Speaker: Daniel Gorovets, MD - Memorial Sloan Kettering Cancer Center, New York
• 02:15pm - 03:30pm ET

  Beyond Margins and Stage: A DNA Damage and Cell-Cycle Checkpoint Transcriptional Phenotype Identifies Durable Benefit from Adjuvant Radiotherapy In Adrenocortical Carcinoma

  Speaker: Julia Balmaceda, MD - WashU Medicine, Saint Louis
• 02:15pm - 03:30pm ET

  Data-Driven Pre-Implant AI Predictions for Supplemental Interstitial Needle Needs In Hybrid Cervix Brachytherapy

  Speaker: Elizabeth Kidd, MD, FASTRO - Stanford University, Stanford